Clinical Trials · NCT07103408
A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer
- Phase
- Phase 2
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Sun Yat-sen University
- Enrollment
- 56
- Start date
- Oct 2025
- Locations
- 1 site, China
- Primary endpoint
- Progression-free survival